A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria

Abstract Background A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to develop a clinical risk assessment score. Methods Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Of these, 100 (28.7%) BM in 48 (53.9%) patients responded with either TR (n = 53, 15%) or PP (n = 47, 14%). Differences between the 2 groups were analyzed and used to develop a risk assessment score (the Bergen Criteria). Results Factors associated with a higher incidence of PP vs. TR were as follows: prior radiation with whole brain radiotherapy or SRS (P = .001), target cover ratio ≥98% (P = .048), BM volume ≤2 cm3 (P = .054), and primary lung cancer vs. other cancer types (P = .084). Based on the presence (0) or absence (1) of these 5 characteristics, the Bergen Criteria was established. A total score <2 points was associated with 100% PP, 2 points with 57% PP and 43% TR, 3 points with 57% TR and 43% PP, whereas >3 points were associated with 84% TR and 16% PP, P < .001. Conclusion Based on 5 characteristics at the time of SRS the Bergen Criteria could robustly differentiate between PP vs. TR following SRS. The score is user-friendly and provides a useful tool to guide the decision making whether to retreat or observe at appropriate follow-up intervals.

[1]  P. Brown,et al.  Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  S. Chandra,et al.  Pseudoprogression of Melanoma Brain Metastases , 2018, Current Oncology Reports.

[3]  S. Lo,et al.  Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases , 2018, Front. Oncol..

[4]  Suneel D. Kamath,et al.  Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease , 2018, Front. Oncol..

[5]  H. Jäger,et al.  Correction to: Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2 , 2018, La radiologia medica.

[6]  R. Colaco,et al.  Radiation Necrosis – A Growing Problem in a Case of Brain Metastases Following Whole Brain Radiotherapy and Stereotactic Radiosurgery , 2018, Cureus.

[7]  H. Jäger,et al.  Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2 , 2018, La radiologia medica.

[8]  P. Delgado-López,et al.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis , 2018, Clinical and Translational Oncology.

[9]  K. Blackwell,et al.  Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis , 2017, Neuro-oncology.

[10]  M. Wiesmann,et al.  O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis , 2017, Neuro-oncology.

[11]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Eide,et al.  Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. , 2017, Journal of neurosurgery.

[13]  J. Sheehan,et al.  The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. , 2017, Journal of neurosurgery.

[14]  K. Peck,et al.  A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. , 2016, Neuro-oncology.

[15]  A. Vortmeyer,et al.  Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment , 2015, Cancer Immunology Research.

[16]  M. McDermott,et al.  Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. , 2015, Journal of neurosurgery.

[17]  D. Kondziolka,et al.  Volumetric response to radiosurgery for brain metastasis varies by cell of origin. , 2014, Journal of neurosurgery.

[18]  D. Rigamonti,et al.  Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice , 2014, Neurosurgical Review.

[19]  J. Ganz,et al.  Gamma knife surgery of colorectal brain metastases: a high prescription dose of 25 Gy may improve growth control. , 2013, World neurosurgery.

[20]  Riemer H. J. A. Slart,et al.  Value of 11C-methionine PET in imaging brain tumours and metastases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  J. Knisely,et al.  A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases , 2011, American Journal of Neuroradiology.

[22]  J. Ganz,et al.  Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. , 2011, World neurosurgery.

[23]  D. Kondziolka,et al.  T1/T2 Matching to Differentiate Tumor Growth From Radiation Effects After Stereotactic Radiosurgery , 2010, Neurosurgery.

[24]  D. Kondziolka,et al.  Differentiating radiation effect from tumor progression after stereotactic radiosurgery: T1/T2 matching. , 2010, Clinical neurosurgery.

[25]  Y. Yoshii.  Pathological review of late cerebral radionecrosis , 2008, Brain Tumor Pathology.

[26]  W. Friedman,et al.  CAN STANDARD MAGNETIC RESONANCE IMAGING RELIABLY DISTINGUISH RECURRENT TUMOR FROM RADIATION NECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES? A RADIOGRAPHIC‐PATHOLOGICAL STUDY , 2008, Neurosurgery.

[27]  G. Barnett,et al.  Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. , 2006, Journal of neurosurgery.

[28]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[29]  K. Ohata,et al.  Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? , 2003, Journal of neurosurgery.